Lungenveränderungen bei COVID-19 – Störung des pulmonalen Surfactants?

Müller B (1995) Effects of environmental factors on the lung surfactant system. Semin Respir Crit Care Med 16:33–60 Ashbaugh DG, Bigelow DB, Petty TL, Levine BE (1967) Acute respiratory distress in adults. Lancet 2:319–323 v Wichert P, Kohl FV (1977) Decreased dipalmitoyllecithin content found in lung specimens from patients with so-called shock-lung Intens. Care Med 3:27–30 MacIntyre NR (1995) Surfactant and the adult repiratory distress syndrome. Semin Respir Crit Care Med 16:47–52 Wichmann D, Sperhake JP, Lütgehetmann M et al (2020) Autopsy findings and venous thromboembolism in patients with Covid-19. Anninter Med. https://doi.org/10.7326/M20-2003 Mason RJ (2020) Pathogenesis of Covid-19 from a cell biologic perspective. Eur Respir J. https://doi.org/10.1183/13993003.00607-2020 v Wichert P (1981) Clinical importance of surfactant defects. Karger, Basel Bösmüller H, Traxler S, Bitzer M et al (2020) The evolution of pulmonary pathology in fatal covid-19 disease: an autopsy study with clinical correlation. Virchows Arch. https://doi.org/10.1007/s00428-020-02881-x Kommoss FKF, Schwab C, Tavernar L et al (2020) Pathologie der schweren covid-19 bedingten Lungenschädigung. Dtsch Ärztebl 117:500–506 v Wichert P, Wilke A, Gärtner U (1975) Einbau von Palmitat-1-14C in Lecithin und Phospholipidgehalt in normalen und mikroembolisierten Kaninchenlungen – Modellstudie zur sog. Schocklunge. Anaesthesist 24:78–83 Horby P, Lim WS, Emberson JR et al (2020) Dexamethasone in hospitalized patients with covid-19—preliminary report. N Engl J Med. https://doi.org/10.1056/NEJMoa2021436